Duke Cancer Institute (DCI) Blog provides updates, organizational announcements, the latest in funding opportunities and information on upcoming conferences and symposiums. This blog also highlights inspiring patient stories and the accomplishments and achievements of DCI faculty and staff. Subscribers are invited to submit story ideas and other news of interest. Email submissions and feedback to Karen E. Butler, Director of Communications, Duke Cancer Institute.

Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept study by Duke Cancer Institute researchers. The study, published June 28 in...

A study by scientists at Duke Health is providing insight into how certain commonly-used chemotherapy drugs work, potentially opening new ways to enhance the benefits of treatment for cancer patients. The scientists focused on antimetabolites, chemotherapy drugs that target metabolism in cancer...

The Investigational Chemotherapy Service is one of two labs making up the Pharmaceutical Shared Resource. Putting a new cancer medication through the early stages of clinical trials is an intimidatingly complex process. A proper dosage regimen must be tailored for every patient. Medications may...

Duke Cancer Center North Durham

Duke Surgical Oncology at North Duke Street

Duke Adult Bone Marrow Transplant Clinic

Connect With Us

Ways To Give

Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.